联合临床因素与FDG PET/CT因素的复合标准预测活体肝移植后肝细胞癌复发
回顾性纳入两个独立中心2005至2013年间239例活体肝移植患者,以肿瘤大小、数目、甲胎蛋白及FDG PET/CT的TBRmax构建复合标准;当肿瘤大小<6.0 cm、数目<8、甲胎蛋白<465 ng/mL、TBRmax<2.8时,预测复发的敏感度为75.7%、特异度为88.5%,其预测复发及无复发生存的表现优于传统受者选择标准。
要点
- 肿瘤大小、数目、甲胎蛋白和TBRmax均为移植后复发的显著预测因素。
- 复合标准 cutoff:肿瘤大小<6.0 cm、数目<8、甲胎蛋白<465 ng/mL、TBRmax<2.8。
- 该复合标准预测复发的敏感度75.7%、特异度88.5%,优于传统标准。
核心结论
- 在临床因素基础上加入FDG PET/CT的TBRmax所构成的复合标准,有助于筛选适合肝移植的肝癌患者。
研究设计与样本
- 回顾性纳入两个独立中心2005至2013年间239例活体肝移植患者,测量PET的TBRmax,采用logistic回归与生存分析筛选预测因素并设计复合标准,行十折交叉验证。
关键影像表现/征象
- FDG PET/CT测量肿瘤最大肿瘤/本底比值(TBRmax)。
- 肿瘤大小、数目、甲胎蛋白和TBRmax被选为复发的显著预测因素。
诊断标准与关键数值
- 复合标准 cutoff 为肿瘤大小<6.0 cm、肿瘤数目<8、甲胎蛋白<465 ng/mL、TBRmax<2.8时,预测复发的敏感度75.7%、特异度88.5%。
临床应用与阅片要点
- 阅片时可测量FDG PET/CT的TBRmax,并与肿瘤大小、数目及血清甲胎蛋白联合用于移植后复发风险评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Fluorodeoxyglucose (FDG) PET/CT is effective for predicting recurrence of hepatocellular carcinoma after liver transplantation. This study aimed to design composite criteria for predicting post-transplantation recurrence using clinical and FDG PET/CT factors.
METHODS: We retrospectively enrolled 239 patients who underwent living donor transplantation in two independent centers between 2005 and 2013. On PET, maximum tumor-to-background ratio (TBRmax) was measured. Significant predictors for recurrence were selected by logistic regression and survival analyses. With varying cutoff values for the selected factors, composite criteria were designed to maximize the predictive performance for recurrence, and tenfold cross-validation was performed. Predictive values were compared between the composite criteria and the conventional recipient selection criteria.
RESULTS: Tumor size, number, alpha-fetoprotein, and TBRmax were selected as significant predictors in both logistic regression and multivariate survival analyses. In combination of these factors, the highest diagnostic performance was sensitivity of 75.7% and specificity of 88.5% with cutoff values of tumor size < 6.0 cm, tumor number < 8, alpha-fetoprotein < 465 ng/mL, and TBRmax < 2.8. The composite criteria exhibited the highest performance for predicting recurrence and recurrence-free survival among the tested criteria including conventional ones.
CONCLUSIONS: The composite criteria adding FDG PET findings to clinical factors are effective in selecting appropriate liver cancer patients who are candidates for liver transplantation.
KEY POINTS: • In patients with HCC, tumor uptake on FDG PET/CT, tumor size, number, and serum AFP level are recognized individual predictors for tumor recurrence after LT. • A composite criterion set, combining tumor size, number, serum AFP level, and maximum tumor-to-background ratio (TBR max ), predicts post-LT recurrence most effectively when compared with conventional criteria sets in selecting candidates for living donor LT.
引用
- Kang YK, Choi JY, Paeng JC, et al. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation. Eur Radiol. 2019. PMID: 31115626. doi:10.1007/s00330-019-06239-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。